Kyle Serikawa

Kyle Serikawa received his PhD in Genetics from the University of California at Berkeley in 1996 and moved to Seattle to pursue postdoctoral research positions in algal development and the cell cycle of yeast. He was an early adopter of microarrays as tools for the genome-wide measurement of transcription in cells and tissues.

Read More


Lisa Suennen

Lisa Suennen is Managing Partner at Venture Valkyrie Consulting, which provides business advisory services to large corporations, not-for-profit institutions, and venture capital and private equity firms in the healthcare field. Her advisory work focused on both investment and digital health strategy that capitalizes on the significant opportunities presented by today’s evolving healthcare system. Lisa is also Managing Member of Cardeation Capital Management.

Read More ➛

Leora Schiff

Leora Schiff is the Founder and Principal of Altius Strategy Consulting, a company that provides product value development planning services to biotechnology, pharmaceutical, diagnostic and medical device companies. She helps companies identify product value propositions for different market stakeholders and plan for the generation of clinical, health economic and quality of life evidence needed to support those value propositions.

Read More ➛

Robert Plenge

Robert Plenge is a former Vice President at MRL in Boston, transitioning to a new job in biopharma in Cambridge. Prior to joining Merck in July 2013, Robert served as Director of Genetics & Genomics in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital; Assistant Professor of Medicine at Harvard Medical School; and Associate Member of the Broad Institute of MIT and Harvard.

Read More

Sam Blackman

Sam Blackman is a physician-scientist trained in pediatric hematology-oncology and pediatric neuro-oncology. He is currently the senior vice president and head of clinical development at Silverback Therapeutics.

For nearly 10 years, he has been focused on the early clinical development of novel cancer therapeutics and has held various positions of increasing responsibility within the pharmaceutical and biotechnology industry.

Read More ➛